

Appl. No. 10/817,449
Amendment
Page 3

Amendments to the Claims:

1. (Currently Amended) A method for treating bladder or urinary tract cancer in a human or veterinary patient, said method comprising the step of administering to the patient a therapeutically effective amount of a compound selected from the group consisting of:

4'-hydroxy-4,2',6'-trimethoxychalcone;

2'-hydroxy-4,4',6'-trimethoxychalcone (Flavokawain A);


2',4'-dihydroxy-4',6'-dimethoxychalcone (Flavokawain C);

2',4,6'-trihydroxy-4-methoxy-3'-prenylchalcone (Xanthogalenol);

2',6',4'-trimethoxy-4'-hydroxy-3'-prenylchalcone; and

pharmaceutically acceptable salts thereof.

having the formula:



Formula 4

wherein;


Appl. No. 10/817,449
 Amendment
 Page 4

~~R₄, R₃, R₅, R₆ and R₇ are selected from H, OH, O Alkyl, O Alkenyl, O Acyl, O Glucosyl, O Sulphate, - Glucoronate and O Amino Acid, halogen, amino, substituted amino and oxygen atom;~~

~~R₂ and R₄ are selected from H, alkyl and alkenyl, wherein the said alkyl and alkenyl groups have from 1 to 10 carbon atoms and up to 4 double bonds; and~~

~~the hydrogen on the α -carbon of the olefinic double bond may or may not be substituted with a methyl, phenyl or substituted phenyl group.~~

2. (Withdrawn) A method according to Claim 1, where R₅ is an oxygen atom that is connect to the β -carbon atom of the olefinic double bond to form a compound having the formula:



Formula 2

wherein;


Appl. No. 10/817,449
Amendment
Page 5

R_1 , R_3 , R_6 and R_7 are selected from H, OH, O-Alkyl, O-Alkenyl, O-Acyl; O-Glucosyl, O-Sulphate, γ -Glucuronate and O-Amino Acid, halogen, amino, substituted amino and oxygen atom;

R_2 and R_4 are selected from H, alkyl and alkenyl, wherein the said alkyl and alkenyl groups have from 1 to 10 carbon atoms and up to 4 double bonds; and

the hydrogen on the α -carbon of the olefinic double bond may or may not be substituted with a methyl, phenyl or substituted phenyl group.

3. (Withdrawn) A method according to Claim 1, where R_2 is prenyl or other alkenyl and R_3 is OH, wherein R_2 and R_3 are combined to form a cyclic ring structure and a compound having the formula :



Formula 3A

wherein;


Appl. No. 10/817,449
Amendment
Page 6

R₁, R₅, R₆ and R₇ are selected from H, OH, O-Alkyl, O-Alkenyl, O-Acyl; O-Glucosyl, O-Sulphate, γ -Glucuronate and O-Amino Acid, halogen, amino, substituted amino and oxygen atom;

R₄ is selected from H, alkyl and alkenyl, wherein the said alkyl and alkenyl groups have from 1 to 10 carbon atoms and up to 4 double bonds; and

the hydrogen on the α -carbon of the olefinic double bond may or may not be substituted with a methyl, phenyl or substituted phenyl group.

4. (Withdrawn) A method according to Claim 1, wherein R₄ is prenyl or other alkyl, R₃ is OH and said R₃ and R₄ are combined to form a cyclic ring structure and a compound of the formula:



Formula 3B

wherein;


Appl. No. 10/817,449
Amendment
Page 7

R_1 , R_5 , R_6 and R_7 are selected from H, OH, O-Alkyl, O-Alkenyl, O-Acyl; O-Glucosyl, O-Sulphate, γ -Glucuronate and O-Amino Acid, halogen, amino, substituted amino and oxygen atom;

R_2 is selected from H, alkyl and alkenyl, wherein the said alkyl and alkenyl groups have from 1 to 10 carbon atoms and up to 4 double bonds; and

the hydrogen on the α -carbon of the olefinic double bond may or may not be substituted with a methyl, phenyl or substituted phenyl group.

5. (Withdrawn) A method according to Claim 1 wherein R_4 is prenyl or other alkyl, R_5 is OH and are combined to form a cyclic ring and a compound having the formula:



Formula 3C


R_1 , R_3 , R_6 and R_7 are selected from H, OH, O-Alkyl, O-Alkenyl, O-Acyl; O-Glucosyl, O-Sulphate, γ -Glucuronate and O-Amino Acid, halogen, amino, substituted amino and oxygen atom;

Appl. No. 10/817,449
Amendment
Page 8

R_2 is selected from H, alkyl and alkenyl, wherein the said alkyl and alkenyl groups have from 1 to 10 carbon atoms and up to 4 double bonds; and

the hydrogen on the α -carbon of the olefinic double bond may or may not be substituted with a methyl, phenyl or substituted phenyl group.

6. (Withdrawn) A method according to Claim 1, where R_2 is prenyl or other alkenyl, R_3 is OH and R_2 and R_3 combine to form a cyclic ring and a compound of formula:



Formula 4A

wherein;


R_1 , R_5 and R_7 are selected from H, OH, O-Alkyl, O-Alkenyl, O-Acyl; O-Glucosyl, O-Sulphate, γ -Glucuronate and O-Amino Acid, halogen, amino, substituted amino and oxygen atom;

R_4 is selected from H, alkyl and alkenyl, wherein the said alkyl and alkenyl groups have from 1 to 10 carbon atoms and up to 4 double bonds; and

Appl. No. 10/817,449
Amendment
Page 9

the hydrogen on the α -carbon of the olefinic double bond may or may not be substituted with a methyl, phenyl or substituted phenyl group.

7. (Withdrawn) A method According to Claim 1 wherein R_4 is prenyl or other alkenyl, R_3 is OH and wherein R_3 and R_4 are combined to form a cyclic ring structure and a compound having the formula:



Formula 4B

wherein;

R_1 , R_6 and R_7 are selected from H, OH, O-Alkyl, O-Alkenyl, O-Acyl; O-Glucosyl, O-Sulphate, γ -Glucuronate and O-Amino Acid, halogen, amino, substituted amino and oxygen atom;

R_2 is selected from H, alkyl and alkenyl, wherein the said alkyl and alkenyl groups have from 1 to 10 carbon atoms and up to 4 double bonds; and

the hydrogen on the α -carbon of the olefinic double bond may or may not be substituted with a methyl, phenyl or substituted phenyl group.

Appl. No. 10/817,449
Amendment
Page 10

8-19. (Cancelled)

20. (Original) A method according to claim 1 wherein the compound is administered orally.

21. (Original) A method according to Claim 1, wherein the compound is administered intravesically.

22. (New) A method according to claim 1 wherein the compound is administered at a dose of from about 0.01 mg per kilogram of body weight per day to about 100 mg/kg of body weight per day, in a single daily dose or divided into more than one daily dose.

23. (New) A method according to claim 1 wherein the compound is administered at a dose of from about 0.05 mg per kilogram of body weight per day to about 50 mg/kg of body weight per day, in a single daily dose or divided into more than one daily dose.

24. (New) A method according to claim 1 wherein the compound is administered at a dose of from about 0.1 mg per kilogram of body weight per day to about 25 mg/kg of body weight per day, in a single daily dose or divided into more than one daily dose.

25. (New) A method according to claim 1 wherein the compound is administered parenterally.

26. (New) A method according to claim 1 wherein the compound is administered in combination with at least one other compound selected from the group consisting of: cisplatin, carboplatin, taxanes, paclitaxel, docetaxel, gemcitabine, ifosfamide, methotrexate, trimetrexate, piritrexim, thiotepa, doxorubicin and mitomycin.